MK 1682
Alternative Names: MK-1682Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections in USA
- 09 Dec 2008 Phase-I clinical trials in Bacterial infections in USA (unspecified route)